Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (27921)	2/6/1999 12:59:00 PM
From: RXGOLF	Respond to of 32384

Henry, I hope you are correct in that Ligand has a strong sales force ready to go to work. As Wallace said, we will now be judged not only on "science", but on sales dollars, sales growth from qtr. to qtr., etc. I do believe that the Ligand sales reps will have a fairly easy job in getting the word out on Ligands products. It is not like Ontak and Panretin are "me too" products that each have to face competition from a multitude of similar products marketed by major pharmacy powers. Greg

To: Henry Niman who wrote (27921)	2/6/1999 3:15:00 PM
From: Mudcat	Read Replies (1) \| Respond to of 32384

<As Bear Stearns indicated on Wednesday, Biotechs traditionally make their biggest price moves right after drugs are approved, and David Molowa did not expect LGND to be an exception> I guess we will have to see what happens on Monday!

To: Henry Niman who wrote (27921)	2/6/1999 4:17:00 PM
From: notyet	Respond to of 32384

up to 6 in the next 15 You write:'With the number of FDA approved drugs growing to 4-6 in the next 12-15 months ...' What are you referring at? Lemme guess! Could you correct me? Oral Panretin for KS Oral Targretin for CTCL Topical Targretin for CTLC Other approvals for Panretin & Targretin? And now a elaborative correction to my post Message 7695603 Recap.com says that 'FDA action is taken' for topical panretin in APL. What were the P3 results? However acc. to Recap.com oral panretin for APL is still in P3. Last one: how has oral targretin been faring in advanced lung cancer, kidney,ovarian and prostate cancer and KS ?